

C2
111-112, respectively. Exons 12-13 correspond to SEQ ID NO: 122-123, respectively. Exon 14 corresponds to SEQ ID NO: 113. Exons 15-16 correspond to SEQ ID NO: 2-3, respectively. Exons 17-21 correspond to SEQ ID NO: 124-129, respectively. Exon 22 corresponds to SEQ ID NO: 114. Exons 23-27 correspond to SEQ ID NO: 129-133, respectively.--

C3
In the claims:

Please amend claim 62 as follows:

62. (Once Amended) The isolated nucleic acid molecule according to claim 61, wherein the nucleotide sequence of the BRCA2 gene further comprises a cytosine at a position corresponding to position 1093 of SEQ ID NO: 134, and wherein the nucleotide at position 1342 is adenine.

REMARKS

I. Summary of the Office Action dated December 1, 2000

1. All of the objections and rejections set forth in the previous office action dated March 16, 2000 were withdrawn in view of cancellation of claims 1-60 and amendments to the specification.
2. The specification was objected to as failing to provide proper antecedent basis for the claimed subject matter because the numbering in the exon sequences in the sequence listing did not indicate their position in the BRCA2 gene sequence.
3. Claims 61-86 were rejected under 35 U.S.C. § 112 (first paragraph) as containing subject matter which was not described in the specification in such a way as to reasonably convey to the skilled artisan that Applicants were in possession of the claimed invention at the time of application filing.